Overactive Bladder pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 112 pages | ID: OAFF14950FE0EN
VPAResearch

Abstracts

2020 Overactive Bladder PIPELINE HIGHLIGHTS
Overactive Bladder is one of the widely researched conditions during 2020 with 25 companies actively focusing on realizing pipeline’s potential. Development of Overactive Bladder medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Overactive Bladder market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Overactive Bladder.

Good progress is anticipated during 2020 and 2021 with Overactive Bladder pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Overactive Bladder pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Overactive Bladder DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Overactive Bladder pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Overactive Bladder pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Overactive Bladder presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Overactive Bladder pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Overactive Bladder DRUG PROFILES
Overactive Bladder development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-

• Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
• Phase of development
• Mechanism of Action
• Route of Administration
• Companies involved including originator, licensing companies, developer, investors, and others
• New molecular entity details
• Orphan drug designation and other special status provided by regulators

Overactive Bladder COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Overactive Bladder drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Overactive Bladder. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 25 Overactive Bladder companies including company overview, key snapshot, contact information, and their strategies on accelerating Overactive Bladder pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Aetas Pharma Co Ltd, Astellas Pharma Inc, DelNova Inc, Dong-A ST Co Ltd, DongKoo Bio & Pharma Co Ltd, Evestra Inc, FemmePharma Global Healthcare Inc, Hanmi Pharmaceuticals Co Ltd, Imbrium Therapeutics LP, Ion Channel Innovations LLC, Kissei Pharmaceutical Co Ltd, Korean Pharmaceuticals, Kyorin Pharmaceutical Co Ltd, Lipella Pharmaceuticals Inc, Medy-Tox Inc, Mezzion Pharma Co Ltd, Mylan NV, Recordati SpA, Taiho Pharmaceutical Co Ltd, TARIS Biomedical, Taris Biomedical LLC, TheraCoat Ltd, TheraVida Inc, Urovant Sciences GmbH, Velicept Therapeutics Inc

REASONS TO BUY

• The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
• This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
• Buyers can identify most promising drug candidates for treatment of Overactive Bladder
• It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
• Users can estimate possible delays in the delivery of pipeline or launch of new products
• Stay ahead of competition through understanding their pipeline progression, strategies and outlook
• The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
• Optimize your licensing and technology transfer strategies through identification of prospect partners

Contents

1. INTRODUCTION TO OVERACTIVE BLADDER

1.1 Overactive Bladder- Disease overview
1.2 Overactive Bladder- Market Size
1.3 Overactive Bladder- Companies Involved

2. OVERACTIVE BLADDER PIPELINE SNAPSHOT- 2020

2.1 Overactive Bladder Pipeline by Phase
2.2 Overactive Bladder Pipeline by Mechanism of Action
2.3 Overactive Bladder Pipeline by Route of Administration
2.4 Overactive Bladder Pipeline- New Molecular Entities
2.5 Overactive Bladder Pipeline- Orphan Drug Designation/ Special Designation

3. OVERACTIVE BLADDER DRUG PROFILES

3.1 Current Status
3.2 Overactive Bladder Drug Snapshot
3.3 Overactive Bladder Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Aetas Pharma Co Ltd Overactive Bladder Pipeline Insights and Clinical Trials
4.2 Astellas Pharma Inc Overactive Bladder Pipeline Insights and Clinical Trials
4.3 DelNova Inc Overactive Bladder Pipeline Insights and Clinical Trials
4.4 Dong-A ST Co Ltd Overactive Bladder Pipeline Insights and Clinical Trials
4.5 DongKoo Bio & Pharma Co Ltd Overactive Bladder Pipeline Insights and Clinical Trials
4.6 Evestra Inc Overactive Bladder Pipeline Insights and Clinical Trials
4.7 FemmePharma Global Healthcare Inc Overactive Bladder Pipeline Insights and Clinical Trials
4.8 Hanmi Pharmaceuticals Co Ltd Overactive Bladder Pipeline Insights and Clinical Trials
4.9 Imbrium Therapeutics LP Overactive Bladder Pipeline Insights and Clinical Trials
4.10 Ion Channel Innovations LLC Overactive Bladder Pipeline Insights and Clinical Trials
4.11 Kissei Pharmaceutical Co Ltd Overactive Bladder Pipeline Insights and Clinical Trials
4.12 Korean Pharmaceuticals Overactive Bladder Pipeline Insights and Clinical Trials
4.13 Kyorin Pharmaceutical Co Ltd Overactive Bladder Pipeline Insights and Clinical Trials
4.14 Lipella Pharmaceuticals Inc Overactive Bladder Pipeline Insights and Clinical Trials
4.15 Medy-Tox Inc Overactive Bladder Pipeline Insights and Clinical Trials
4.16 Mezzion Pharma Co Ltd Overactive Bladder Pipeline Insights and Clinical Trials
4.17 Mylan NV Overactive Bladder Pipeline Insights and Clinical Trials
4.18 Recordati SpA Overactive Bladder Pipeline Insights and Clinical Trials
4.19 Taiho Pharmaceutical Co Ltd Overactive Bladder Pipeline Insights and Clinical Trials
4.20 TARIS Biomedical Overactive Bladder Pipeline Insights and Clinical Trials
4.21 Taris Biomedical LLC Overactive Bladder Pipeline Insights and Clinical Trials
4.22 TheraCoat Ltd Overactive Bladder Pipeline Insights and Clinical Trials
4.23 TheraVida Inc Overactive Bladder Pipeline Insights and Clinical Trials
4.24 Urovant Sciences GmbH Overactive Bladder Pipeline Insights and Clinical Trials
4.25 Velicept Therapeutics Inc Overactive Bladder Pipeline Insights and Clinical Trials

5. OVERACTIVE BLADDER MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology
6.2 Contact Information